{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:43:46Z","timestamp":1791474226609,"version":"4.3.4"},"reference-count":159,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.semnephrol.2023.151436","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T07:02:31Z","timestamp":1699599751000},"page":"151436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["HUS and TTP: traversing the disease and the age spectrum"],"prefix":"10.1016","volume":"43","author":[{"given":"Roberta","family":"Donadelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Noris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0001","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1046\/j.1523-1755.2001.060003831.x","article-title":"Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura","volume":"60","author":"Ruggenenti","year":"2001","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0002","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2001-12-0166","article-title":"von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome","volume":"100","author":"Remuzzi","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0003","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ki.1987.206","article-title":"HUS and TTP: variable expression of a single entity","volume":"32","author":"Remuzzi","year":"1987","journal-title":"Kidney Int"},{"issue":"9464","key":"10.1016\/j.semnephrol.2023.151436_bib0004","first-page":"1073","article-title":"Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome","volume":"365","author":"Tarr","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.semnephrol.2023.151436_bib0005","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: State of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151436_bib0007","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in Secondary Thrombotic Microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12020067","article-title":"Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review","volume":"12","author":"Joseph","year":"2020","journal-title":"Toxins (Basel)"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1089\/fpd.2013.1704","article-title":"Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis","volume":"11","author":"Majowicz","year":"2014","journal-title":"Foodborne Pathog Dis"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0011","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.medmal.2017.09.012","article-title":"Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection","volume":"48","author":"Bruyand","year":"2018","journal-title":"Med Mal Infect"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151436_bib0012","first-page":"e06971","article-title":"European Centre for Disease Prevention and Control, The European Union One Health 2020 Zoonoses Report","volume":"19","year":"2021","journal-title":"EFSA J"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151436_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9071529","article-title":"Shiga Toxin-Producing Escherichia coli Outbreaks in the United States, 2010-2017","volume":"9","author":"Tack","year":"2021","journal-title":"Microorganisms"},{"issue":"9796","key":"10.1016\/j.semnephrol.2023.151436_bib0014","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(11)61217-8","article-title":"A German outbreak of haemolytic uraemic syndrome","volume":"378","author":"Ruggenenti","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijid.2018.09.002","article-title":"Non-O157 Shiga toxin-producing Escherichia coli-A poorly appreciated enteric pathogen: Systematic review","volume":"76","author":"Valilis","year":"2018","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151436_bib0016","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001375","article-title":"The emerging importance of Shiga toxin-producing Escherichia coli other than serogroup O157 in England","volume":"70","author":"Vishram","year":"2021","journal-title":"J Med Microbiol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0017","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/lam.13295","article-title":"Antibody response to lipopolysaccharides and recombinant proteins of Shiga toxin (STX)-producing Escherichia coli (STEC) in children with haemolytic uraemic syndrome in Poland","volume":"70","author":"Rastawicki","year":"2020","journal-title":"Lett Appl Microbiol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms7010015","article-title":"Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome","volume":"7","author":"Buelli","year":"2019","journal-title":"Microorganisms"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0019","doi-asserted-by":"crossref","first-page":"e59372","DOI":"10.1371\/journal.pone.0059372","article-title":"Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis","volume":"8","author":"Turner","year":"2013","journal-title":"PLoS One"},{"issue":"9135","key":"10.1016\/j.semnephrol.2023.151436_bib0020","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)01267-7","article-title":"Escherichia coli O157:H7","volume":"352","author":"Mead","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151436_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13050306","article-title":"Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management","volume":"13","author":"Travert","year":"2021","journal-title":"Toxins (Basel)"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0022","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1532-5415.2011.03269.x","article-title":"Postdiarrheal hemolytic uremic syndrome in persons aged 65 and older in foodnet sites, 2000-2006","volume":"59","author":"Gould","year":"2011","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0023","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/aje\/kwt069","article-title":"Associations of age and sex with the clinical outcome and incubation period of Shiga toxin-producing Escherichia coli O104:H4 infections, 2011","volume":"178","author":"Werber","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151436_bib0024","doi-asserted-by":"crossref","first-page":"e904","DOI":"10.1097\/CCM.0000000000003292","article-title":"Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes","volume":"46","author":"Joseph","year":"2018","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151436_bib0025","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2141.2008.07116.x","article-title":"Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison","volume":"141","author":"Karpac","year":"2008","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151436_bib0026","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3201\/eid2707.204638","article-title":"Shiga Toxin-Associated Hemolytic Uremic Syndrome in Adults, France, 2009-2017","volume":"27","author":"Travert","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0027","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00431-021-04200-1","article-title":"Neurological involvement in children with hemolytic uremic syndrome","volume":"181","author":"Costigan","year":"2022","journal-title":"Eur J Pediatr"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151436_bib0028","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00467-018-4105-1","article-title":"Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS)","volume":"34","author":"Khalid","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"Pt 6","key":"10.1016\/j.semnephrol.2023.151436_bib0029","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/brain\/aws090","article-title":"The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak","volume":"135","author":"Magnus","year":"2012","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0030","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1097\/pq9.0000000000000517","article-title":"Improving Care for Children with Bloody Diarrhea at Risk for Hemolytic Uremic Syndrome","volume":"7","author":"Burns","year":"2022","journal-title":"Pediatr Qual Saf"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0031","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpeds.2021.06.048","article-title":"Bloody Diarrhea and Shiga Toxin-Producing Escherichia coli Hemolytic Uremic Syndrome in Children: Data from the ItalKid-HUS Network","volume":"237","author":"Ardissino","year":"2021","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0032","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00467-016-3496-0","article-title":"Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome","volume":"32","author":"Westra","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151436_bib0033","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1007\/s00431-021-04016-z","article-title":"Hemoglobinuria for the early identification of STEC-HUS in high-risk children: data from the ItalKid-HUS Network","volume":"180","author":"Capone","year":"2021","journal-title":"Eur J Pediatr"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151436_bib0034","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1007\/s00467-021-05108-6","article-title":"Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS)","volume":"36","author":"Loos","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151436_bib0035","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s00467-015-3147-x","article-title":"Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome","volume":"30","author":"Cobe\u00f1as","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0036","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/archdischild-2016-311377","article-title":"Treatment and management of children with haemolytic uraemic syndrome","volume":"103","author":"Walsh","year":"2018","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0037","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.tmrv.2016.06.004","article-title":"Clinical and Laboratory Consequences of Platelet Transfusion in Shiga Toxin-Mediated Hemolytic Uremic Syndrome","volume":"31","author":"Beneke","year":"2017","journal-title":"Transfus Med Rev"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0038","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00467-013-2414-y","article-title":"Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome","volume":"28","author":"Balestracci","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151436_bib0039","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00467-012-2374-7","article-title":"Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome","volume":"28","author":"Caletti","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0040","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151436_bib0041","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10157-014-0995-9","article-title":"Guidelines for the management and investigation of hemolytic uremic syndrome","volume":"18","author":"Igarashi","year":"2014","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0042","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/1744-9987.12768","article-title":"Is Plasma Exchange Efficacious in Shiga Toxin-Associated Hemolytic Uremic Syndrome? A Narrative Review of Current Evidence","volume":"23","author":"Keenswijk","year":"2019","journal-title":"Ther Apher Dial"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151436_bib0043","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.2012.264","article-title":"Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4","volume":"307","author":"Nitschke","year":"2012","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151436_bib0044","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/jac\/dkv162","article-title":"Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal","volume":"70","author":"Agger","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151436_bib0045","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/cid\/ciw099","article-title":"Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis","volume":"62","author":"Freedman","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151436_bib0046","article-title":"Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome","volume":"7","author":"Imdad","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151436_bib0047","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0048","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ndt\/gft470","article-title":"Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab","volume":"29","author":"Delmas","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151436_bib0049","doi-asserted-by":"crossref","first-page":"e27913","DOI":"10.1002\/pbc.27913","article-title":"Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence","volume":"66","author":"Mahat","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151436_bib0050","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-012-2383-6","article-title":"Long-term outcomes of Shiga toxin hemolytic uremic syndrome","volume":"28","author":"Spinale","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0051","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1542\/peds.94.1.35","article-title":"A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah","volume":"94","author":"Siegler","year":"1994","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0052","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s004670050248","article-title":"Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features","volume":"11","author":"Spizzirri","year":"1997","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151436_bib0053","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00467-003-1262-6","article-title":"Risk factors for poor renal prognosis in children with hemolytic uremic syndrome","volume":"18","author":"Gianviti","year":"2003","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151436_bib0054","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00467-014-2803-x","article-title":"Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome","volume":"29","author":"Bauer","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ndt\/gfv255","article-title":"Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults","volume":"31","author":"Derad","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0056","doi-asserted-by":"crossref","first-page":"e2337","DOI":"10.1097\/MD.0000000000002337","article-title":"Neurological Sequelae in Adults After E coli O104: H4 Infection-Induced Hemolytic-Uremic Syndrome","volume":"95","author":"Schuppner","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0057","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/pathogens10060727","article-title":"Streptococcus Pneumoniae-Associated Hemolytic Uremic Syndrome in the Era of Pneumococcal Vaccine","volume":"10","author":"Agarwal","year":"2021","journal-title":"Pathogens"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0058","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","article-title":"Update on Streptococcus pneumoniae associated hemolytic uremic syndrome","volume":"25","author":"Spinale","year":"2013","journal-title":"Curr Opin Pediatr"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151436_bib0059","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1097\/INF.0000000000002368","article-title":"Pneumococcal-related Hemolytic Uremic Syndrome in the United Kingdom: National Surveillance, 2006-2016","volume":"38","author":"Makwana","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151436_bib0060","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00467-021-04952-w","article-title":"Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome","volume":"36","author":"Holle","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.641656","article-title":"Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome","volume":"12","author":"G\u00f3mez Delgado","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0062","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1111\/ped.12166","article-title":"Decreased sialylation of IgA1 O-glycans associated with pneumococcal hemolytic uremic syndrome","volume":"55","author":"Aoki","year":"2013","journal-title":"Pediatr Int"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151436_bib0063","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00467-019-04342-3","article-title":"New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome","volume":"35","author":"Scobell","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0064","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(06)70411-X","article-title":"Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining?","volume":"6","author":"Obaro","year":"2006","journal-title":"The Lancet Infectious Diseases"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151436_bib0065","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/01.inf.0000223494.83542.ad","article-title":"T-antigen activation for prediction of pneumococcus-induced hemolytic uremic syndrome and hemolytic anemia","volume":"25","author":"Huang","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0066","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/trf.12981","article-title":"Red blood cell Thomsen-Friedenreich antigen expression and galectin-3 plasma concentrations in Streptococcus pneumoniae-associated hemolytic uremic syndrome and hemolytic anemia","volume":"55","author":"Burin des Roziers","year":"2015","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0067","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00467-021-05053-4","article-title":"Treatment strategy for Streptococcus pneumoniae-associated hemolytic uremic syndrome","volume":"36","author":"Madden","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151436_bib0068","doi-asserted-by":"crossref","first-page":"e29082","DOI":"10.1002\/pbc.29082","article-title":"Erythrocyte T-antigen activation in children: Patient characteristics and the hemolytic risk of transfusion","volume":"68","author":"Jacquot","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0069","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0070","first-page":"1","article-title":"Acute and chronic histopathological findings in renal biopsies in COVID-19","author":"Volbeda","year":"2022","journal-title":"Clin Exp Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0071","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10157-012-0656-9","article-title":"Thrombotic microangiopathy and acute kidney injury following vivax malaria","volume":"17","author":"Sinha","year":"2013","journal-title":"Clin Exp Nephrol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151436_bib0072","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ajh.22091","article-title":"Systemic infections mimicking thrombotic thrombocytopenic purpura","volume":"86","author":"Booth","year":"2011","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151436_bib0073","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00467-019-04233-7","article-title":"Hemolytic uremic syndrome in a developing country: Consensus guidelines","volume":"34","author":"Bagga","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151436_bib0074","first-page":"28","article-title":"P. vivax Malaria presenting as Thrombotic Microangiopathy","volume":"65","author":"Bhadauria","year":"2017","journal-title":"J Assoc Physicians India"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151436_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009790","article-title":"Thrombotic microangiopathy associated with arboviral infection: Report of 3 cases","volume":"15","author":"Coelho J\u00fanior","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151436_bib0076","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151436_bib0077","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0078","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0079","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151436_bib0080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00281-014-0416-x","article-title":"Hemolytic uremic syndrome","volume":"36","author":"Mele","year":"2014","journal-title":"Semin Immunopathol"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151436_bib0081","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.2021012037","article-title":"Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification","volume":"138","author":"Mart\u00edn Merinero","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0082","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1681\/ASN.2013121339","article-title":"A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1\/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation","volume":"26","author":"Valoti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0083","article-title":"CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome","volume":"13","author":"Piras","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151436_bib0084","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151436_bib0085","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ki.2009.472","article-title":"Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome","volume":"77","author":"Bienaime","year":"2010","journal-title":"Kidney Int"},{"issue":"13","key":"10.1016\/j.semnephrol.2023.151436_bib0086","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fr\u00e9meaux-Bacchi","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151436_bib0087","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0088","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/jth.13210","article-title":"Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes","volume":"14","author":"Peyvandi","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0089","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"13","key":"10.1016\/j.semnephrol.2023.151436_bib0090","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.2020006931","article-title":"Familial risk of developing atypical hemolytic-uremic syndrome","volume":"136","author":"Arjona","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0091","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3389\/fimmu.2019.00853","article-title":"Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS","volume":"10","author":"Valoti","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0092","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6904858","article-title":"Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome","volume":"2021","author":"Shawky","year":"2021","journal-title":"Int J Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0093","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/ped.12549","article-title":"Atypical hemolytic uremic syndrome: Korean pediatric series","volume":"57","author":"Lee","year":"2015","journal-title":"Pediatr Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151436_bib0094","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.931210","article-title":"Anti-factor H antibody and its role in atypical hemolytic uremic syndrome","volume":"13","author":"Raina","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151436_bib0096","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic Uremic Syndrome in Pregnancy and Postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"19","key":"10.1016\/j.semnephrol.2023.151436_bib0097","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151436_bib0098","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ekir.2021.01.034","article-title":"Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes","volume":"6","author":"Timmermans","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"10095","key":"10.1016\/j.semnephrol.2023.151436_bib0099","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fped.2014.00097","article-title":"Extra-renal manifestations of complement-mediated thrombotic microangiopathies","volume":"2","author":"Hofer","year":"2014","journal-title":"Front Pediatr"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0101","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nrneph.2013.280","article-title":"Cardiovascular complications in atypical haemolytic uraemic syndrome","volume":"10","author":"Noris","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151436_bib0102","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2019.216903","article-title":"Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome","volume":"104","author":"El Karoui","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151436_bib0103","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0104","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0106","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminhematol.2018.04.009","article-title":"Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome","volume":"55","author":"Fakhouri","year":"2018","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151436_bib0107","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0108","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0109","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00467-022-05683-2","article-title":"The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review","volume":"38","author":"de Souza","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"18","key":"10.1016\/j.semnephrol.2023.151436_bib0110","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0111","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","article-title":"Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study","volume":"8","author":"Bouwmeester","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0112","article-title":"Interventions for atypical haemolytic uraemic syndrome","volume":"3","author":"Pugh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151436_bib0113","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"10","author":"Noris","year":"2010","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151436_bib0114","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151436_bib0115","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/jcm8070919","article-title":"Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis","volume":"8","author":"Gonzalez Suarez","year":"2019","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151436_bib0116","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0117","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2215\/CJN.08520814","article-title":"Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome","volume":"10","author":"Mele","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0118","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1681\/ASN.2012090903","article-title":"DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN","volume":"24","author":"Ozaltin","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0119","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.kint.2020.01.045","article-title":"Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy","volume":"97","author":"Brocklebank","year":"2020","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151436_bib0120","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1681\/ASN.2017010031","article-title":"The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase \u03b5","volume":"28","author":"Azukaitis","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0121","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.605889","article-title":"Case Report: Denys-Drash Syndrome With WT1 Causative Variant Presenting as Atypical Hemolytic Uremic Syndrome","volume":"8","author":"Cheng","year":"2020","journal-title":"Front Pediatr"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151436_bib0122","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00467-016-3399-0","article-title":"Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity","volume":"32","author":"Beck","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0123","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000497822","article-title":"Do not Miss Rare and Treatable Cause of Early-Onset Hemolytic Uremic Syndrome: Cobalamin C Deficiency","volume":"142","author":"Topaloglu","year":"2019","journal-title":"Nephron"},{"issue":"43","key":"10.1016\/j.semnephrol.2023.151436_bib0124","doi-asserted-by":"crossref","first-page":"e8284","DOI":"10.1097\/MD.0000000000008284","article-title":"Atypical hemolytic uremic syndrome induced by CblC subtype of methylmalonic academia: A case report and literature review","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0125","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0126","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.119.13714","article-title":"Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy","volume":"75","author":"Timmermans","year":"2020","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151436_bib0127","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151436_bib0128","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement Activation and Thrombotic Microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0129","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0130","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.kint.2019.04.011","article-title":"Defects in complement and \u201csecondary\u201d hemolytic uremic syndrome","volume":"96","author":"Timmermans","year":"2019","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12882-022-02672-3","article-title":"What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study","volume":"23","author":"Halimi","year":"2022","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0132","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0133","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","article-title":"De novo thrombotic microangiopathy after kidney transplantation","volume":"32","author":"Garg","year":"2018","journal-title":"Transplant Rev (Orlando)"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151436_bib0134","first-page":"565","article-title":"Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments","volume":"12","author":"Chapin","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151436_bib0135","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.13107","article-title":"Pediatric thrombotic thrombocytopenic purpura","volume":"101","author":"Joly","year":"2018","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0136","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10030536","article-title":"Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management","volume":"10","author":"Sukumar","year":"2021","journal-title":"J Clin Med"},{"issue":"15","key":"10.1016\/j.semnephrol.2023.151436_bib0137","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura","volume":"133","author":"Alwan","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151436_bib0138","doi-asserted-by":"crossref","first-page":"e28949","DOI":"10.1002\/pbc.28949","article-title":"Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children","volume":"68","author":"Siddiqui","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151436_bib0139","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151436_bib0140","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151436_bib0141","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"Vesely","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151436_bib0142","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.2215\/CJN.01700215","article-title":"ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment","volume":"10","author":"Rurali","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151436_bib0143","doi-asserted-by":"crossref","first-page":"e931","DOI":"10.1097\/CCM.0000000000005164","article-title":"Pattern of Brain Injury in Patients With Thrombotic Thrombocytopenic Purpura in the Precaplacizumab Era","volume":"49","author":"Mirouse","year":"2021","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151436_bib0144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256024","article-title":"Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era","volume":"16","author":"Van de Louw","year":"2021","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151436_bib0145","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100945","article-title":"Advances in the management of TTP","volume":"55","author":"Subhan","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0147","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.836960","article-title":"Molecular Diagnosis Is Vital to the Accurate Classification and Management of Thrombotic Thrombocytopenic Purpura in Children","volume":"13","author":"Karsenty","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151436_bib0148","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151436_bib0149","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/bloodadvances.2017009308","article-title":"Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura","volume":"1","author":"Cataland","year":"2017","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151436_bib0150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151436_bib0151","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151436_bib0152","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0153","doi-asserted-by":"crossref","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151436_bib0154","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1160\/TH07-12-0753","article-title":"Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies","volume":"101","author":"Bresin","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semnephrol.2023.151436_bib0155","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720902904","article-title":"Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura","volume":"11","author":"Hanlon","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"25","key":"10.1016\/j.semnephrol.2023.151436_bib0156","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.2020009801","article-title":"Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura","volume":"137","author":"Tarasco","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0157","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/bloodadvances.2021005760","article-title":"Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura","volume":"6","author":"Borogovac","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151436_bib0158","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151436_bib0159","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4049\/jimmunol.1601121","article-title":"Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis","volume":"199","author":"Bettoni","year":"2017","journal-title":"J Immunol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:46:55Z","timestamp":1748357215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523001468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":159,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0270929523001468"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151436","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HUS and TTP: traversing the disease and the age spectrum","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151436"}}